Untreated expansion of cystic craniopharyngiomas can have significant consequences from mass effect including worsening headache, vision loss, and obstructive hydrocephalus. Conventional surgical treatments include attempted resection, typically via craniotomy. Less invasive aspiration of cystic contents only provides a temporary solution, with cysts tending to refill and expand after a single drainage.
Untreated expansion of cystic craniopharyngiomas can have significant consequences from mass effect including worsening headache, vision loss, and obstructive hydrocephalus. Conventional surgical treatments include attempted resection, typically via craniotomy. Less invasive aspiration of cystic contents only provides a temporary solution, with cysts tending to refill and expand after a single drainage. 1 The beneficial effects of intracavitary irradiation for treatment of cystic craniopharyngiomas as a means to abolish the secretory capability of the cyst's epithelial lining, while sparing nearby critical brain structures, has been previously reported.
2-4 90
Yttrium colloid is considered a suitable isotope for treatment of cystic craniopharyngiomas because of its short half-life and pure β emission.
1,2 Intracavitary irradiation with stereotactically implanted 90 yttrium colloid has been shown to be effective in longterm shrinkage of the cystic portion of recurrent craniopharyngiomas. A retrospective review of 78 patients over a 36-year period showed sustained cyst reduction in 63% of patients following 90 yttrium colloid treatment, with 33% of cysts disappearing completely. 2 The administered dose is calculated based on delivering 200 Gy to the inner wall of the cyst. 1, 5 Although radiation delivery into the cyst using a stereotactically guided needle had been previously outlined in Pollack et al, 3 imaging techniques to demonstrate the ongoing intracystic radiation have not been previously described. Although Bremsstrahlung single-photon emission computed tomography/computed tomography (CT) can be used to image the activity distribution after administration of 90 yttrium colloid, positron emission tomography (PET)-CT has become the preferred modality in the brain because of higher spatial and energy resolution . 6 In this report, we demonstrate the use of PET-CT imaging, fused to anatomic CT and magnetic resonance imaging (MRI), as a means of documenting the actual distribution of 90 yttrium colloid delivered to the cystic craniopharyngioma.
METHODS
As part of a Health Canada Phase III clinical trial (NCT02081768), informed consent was obtained from patients treated with 90 yttrium colloid for a suprasellar cystic craniopharyngioma (surgical methods described elsewhere 3 ) to undergo PET-CT 24 to 48 hours postoperatively. PET-CT was performed on a Discovery STE16 camera (General Electric Medical Systems, Milwaukee, WI), to delineate the distribution of the 90 yttrium colloid within the cyst. Although 90 yttrium is primarily a beta emitter and does not directly emit radiation amenable to imaging, it decays to 89 zirconium, which emits a positron/electron pair, making it possible to image the radioisotope with a PET-CT scanner. Images were coregistered with MRI done on the same day. PET imaging consisted of one bed position (15 cm) centered on the sella, in 3 dimensions, 20 minutes, Vue point algorithm, 128 × 128 matrix. Given the lack of anatomic reference on the PET scan, a low-dose CT scan was performed at the same time with a helical scan (0.8 seconds), 3.75-mm slice thickness, 140 kV, 95 mA, and 512 × 512 matrix. The reconstructed 90 yttrium colloid PET voxels have a spatial resolution of approximately 12 mm full width half maximum; the spatial correspondence between the PET and CT scans is less than 5 mm, the approximate size of one PET voxel. The CT provided anatomical landmarks and was used to facilitate attenuation correction of the PET data. PET/CT and MRI scans were coregistered using Statistical Parametric Mapping software (SPM5, Wellcome Trust Centre for Neuroimaging) and fused images displayed using Rview (version 9.073, Colin Studholme).
RESULTS
The images shown in Figure 1 are from a patient treated with 90 yttrium colloid for a suprasellar cystic craniopharyngioma as part of the trial. PET imaging data have been fused to both anatomical CT (top) and MRI (middle) scans.
CONCLUSIONS
We have used PET-CT imaging to characterize the distribution of 90 yttrium colloid delivered to a cystic craniopharyngioma. Image fusion to anatomical imaging (CT and/or MRI) confirms successful injection into the target site, assesses the distribution of 90 yttrium colloid within all of the cyst, and may provide a means to evaluate leakage of 90 yttrium colloid. Further studies will determine whether PET/CT/MRI proves useful in predicting short-and long-term treatment responses.
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